By Colin KellaherShares of CinCor Pharma Inc. more than doubled in premarket trading Monday after the clinical-stage biopharmaceutical company agreed to be acquired by Anglo-Swedish pharmaceutical giant AstraZeneca PLC for up to $1.8 billion. AstraZeneca said it would pay an initial $26 a share in cash for CinCor, roughly 121% above Friday's closing price of $11.78 for the Waltham, Mass., company.

Source: Wall Street Journal January 10, 2023 00:13 UTC